Cellino
Contact SalesAI-driven stem cell biomanufacturing for personalized regenerative medicine.
By Tanmay Verma, Founder · Last verified 03 Jun 2026
4.0k views
Added 10d ago
76/100Safe BetAI-driven stem cell biomanufacturing for personalized regenerative medicine.
By Tanmay Verma, Founder · Last verified 03 Jun 2026
Affiliate disclosure: We earn a commission when you use our links. Editorial picks are independent. How we choose.
See what real users actually say. We scan live discussions, reviews and complaints across the web and hand you an honest verdict — in under a minute.
3 free scans · no card needed · downloadable report
A bold vision for automated stem cell therapy manufacturing, but still early-stage for clinical deployment. Impressive tech stack, but real-world results and regulatory milestones are yet to be proven.
Compare with: Cellino vs Recursion, Cellino vs Owkin, Cellino vs Persana AI
Last verified: June 2026
Cellino is tackling one of the hardest problems in biotech: automating the production of personalized stem cell therapies. Their use of AI, laser optics, and modular hardware (Nebula) is genuinely innovative and could solve scalability issues that plague the field. However, the website is light on clinical data and timelines. Degenerative diseases like Parkinson’s and Alzheimer’s are ambitious targets—expect long R&D cycles. Compared to competitors like BlueRock Therapeutics, Cellino’s automated approach may reduce costs, but it’s years from market. For now, Cellino is best suited for researchers and pharma partners exploring regenerative manufacturing, not for patients seeking immediate treatments.
Skip Cellino if Skip Cellino if you need an off-the-shelf, FDA-approved cell therapy manufacturing platform available today, as the system is still in development and not yet commercial.
How likely is Cellino to still be operational in 12 months? Based on 6 signals including funding, development activity, and platform risk.
Cellino is a biotechnology company pioneering personalized regenerative medicine through AI-driven optical bioprocesses. The company’s proprietary technology stack—including deep learning, laser cell management, and the Nebula™ platform—enables scalable, patient-specific biomanufacturing of cell, tissue, and organ replacements. Targeting degenerative diseases such as macular degeneration, Parkinson’s, and diabetes, Cellino’s approach eliminates the need for immunosuppression by using self-sourced therapies. The Cellinoverse digital environment simulates biomanufacturing in silico, while laser-generated bubbles precisely remove unwanted cells. With the Nebula platform, Cellino compresses traditional infrastructure into modular cassette-based systems for distributed or localized production. Compared to traditional manual methods, Cellino’s AI algorithms deliver reproducible, scalable manufacturing, aiming to expand patient access to living medicines.
Tell us what you want to build — we'll match the AI tools that fit your goal, budget & existing stack.
Concrete scenarios for the personas Cellino actually fits — and what changes day-one when you adopt it.
You are evaluating automated platforms for iPSC-derived therapy scale-up. You deploy Nebula cassettes in your facility, input your proprietary differentiation protocol, and use Cellinoverse to simulate yields and purity across donor backgrounds.
Outcome: You achieve reproducible cell batches with reduced manual intervention, and you identify optimal process parameters in silico before wet-lab runs, saving months of development time.
Your hospital plans to offer patient-specific cell therapies for macular degeneration. You partner with Cellino to install a Nebula system in your GMP cleanroom, and you train your staff on the closed-loop optical bioprocess.
Outcome: Patients receive autologous retinal pigment epithelium cells manufactured on-site, eliminating immunosuppression and wait times for centralized manufacturing slots.
You identify automated cell manufacturing as a growing service line. You negotiate a co-development agreement with Cellino to offer Nebula-based production to your clients targeting Parkinson's and diabetes.
Outcome: You expand your service portfolio with a differentiated AI-guided platform, attracting early-stage biotechs that need reproducible, scalable manufacturing for IND-enabling studies.
Cellino's platform is not yet commercially available; the company is in development and partnership phases. No pricing or API access is currently public. The technology requires deep expertise in cell biology and automation, and it may be several years before regulatory clearance and widespread deployment.
The company stage and team size where Cellino's pricing actually pencils out — and where peers do it cheaper.
Cellino has not published pricing and is pre-commercial. The platform targets large-scale personalized therapy manufacturing, so pricing will likely be structured as partnership or licensing deals. Compared to traditional manual cell culture, automation could lower per-dose costs significantly, but upfront investment and risk are high. No direct cost comparison with peers like Lonza or Fujifilm is possible until Cellino releases pricing.
How long it actually takes to get something useful out of Cellino — broken out by persona, not the marketing-page minute.
For a new partnership, expect 6-12 months for process development, validation, and staff training before initial production runs. The Cellinoverse digital twin can accelerate simulation-based process optimization prior to physical setup. Hospital deployment may require additional facility modifications and GMP certification, extending timeline to 18 months.
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
Pricing, brand, ownership, or deprecation changes worth knowing before you commit. Most-recent first.
Common stack mates teams adopt alongside Cellino, with the specific reason each pairing earns its keep.
Used Cellino? Help shape our editorial sentiment research.
© 2026 RightAIChoice. All rights reserved.
Built for the AI community.
Last calculated: May 2026
AI-powered sales prospecting platform with 100+ data sources.
